Skip to main content
. 2020 Sep 1;10(9):2832–2850.

Figure 1.

Figure 1

SLFN5 is downregulated in BRCA, and this downregulation is associated with tumour progression. A. The transcriptional level (FPKM value) of SLFN5 in BRCA and normal samples from the TCGA database. B. Correlation analysis was performed between the expression level of SLFN5 and clinical TNM stages. C. Correlation analysis was performed between the expression level of SLFN5 and primary tumour size. D. HE and SLFN5 immunohistochemical staining images of human adjacent normal tissues and BRCA tissues. E. Correlation analysis was performed between the immunohistochemical scores of SLFN5 and primary tumour size (n = 75). F. The protein levels of SLFN5 in the BRCA cell lines T47D, MDA-MB-231, MCF-7 and BT549. The protein levels of SLFN5 in MCF-7 cells with SLFN5 knockdown and in MDA-MB-231 cells with SLFN5 overexpression. G and H. SLFN5-overexpressing MDA-MB-231 cells were subcutaneously injected into nude mice, and representative tumour tissues were observed after 4 weeks. I. Tumour volumes were measured every four days. J. 28 days after implantation, the mice were euthanized, and the tumour nodules were weighed. HE & IHC, 100 × (black box), 400 × (blue box). *P < 0.05, **P < 0.01, ***P < 0.001.